Masoud Azizad
- Infectious Diseases top 10%
- Surgery
- Epidemiology
- Cardiology and Cardiovascular Medicine
- Molecular Biology
- Co-authors
- William A. FischerJoseph J. EronKatyna Borroto–EsodaRobert W. CoombsWayne HolmanMyron S. CohenElizabeth R. DukeKatie R. Mollan
- Topics
- SARS-CoV-2 and COVID-19 Research (3 papers)Respiratory viral infections research (2 papers)Lipid metabolism and disorders (2 papers)
- Partner nations
- United StatesAustraliaCanada
In The Last Decade
Masoud Azizad
6 papers receiving 355 citations
Hit Papers
Peers
Comparison fields: 5 of 66
- Infectious Diseases 206
- Surgery 70
- Epidemiology 68
- Cardiology and Cardiovascular Medicine 61
- Molecular Biology 58
Countries citing papers authored by Masoud Azizad
This map shows the geographic impact of Masoud Azizad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masoud Azizad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masoud Azizad more than expected).
Fields of papers citing papers by Masoud Azizad
This network shows the impact of papers produced by Masoud Azizad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masoud Azizad. The network helps show where Masoud Azizad may publish in the future.
Co-authorship network of co-authors of Masoud Azizad
This figure shows the co-authorship network connecting the top 25 collaborators of Masoud Azizad. A scholar is included among the top collaborators of Masoud Azizad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masoud Azizad. Masoud Azizad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemiabreakdown → | 103 |
| 3 | 0 | |
| 4 | 4 | |
| 5 | 2 | |
| 6 | Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients | 6 |
| 7 | A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virusbreakdown → | 230 |
| 8 | Use of prostacyclin and its analogues in the treatment of cardiovascular disease. | 19 |
About Masoud Azizad
Masoud Azizad is a scholar working on Infectious Diseases, Cancer Research and Endocrinology, Diabetes and Metabolism, having authored 8 papers that have together received 364 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (3 papers), Respiratory viral infections research (2 papers) and Lipid metabolism and disorders (2 papers). The work is most often cited by research in Infectious Diseases (206 citations), Endocrinology, Diabetes and Metabolism (51 citations) and Neurology (42 citations). Masoud Azizad has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include William A. Fischer, Joseph J. Eron, Katyna Borroto–Esoda, Robert W. Coombs, Wayne Holman, Myron S. Cohen, Elizabeth R. Duke, Katie R. Mollan, Amy James Loftis and Ralph S. Baric. Their work appears in journals such as New England Journal of Medicine, Circulation and Science Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.